[
  {
    "ts": "2025-11-18T15:33:00+00:00",
    "headline": "Cervical Dystonia Research Analysis Report 2025-2035: Market Sees Intense Competition as Ipsen, Merz, and AbbVie Advance Therapies Through Strategic Expansions",
    "summary": "The global cervical dystonia market is thriving, driven by increased disease prevalence, advancements in neuromodulation techniques, and heightened awareness of movement disorders. Key factors include the widespread adoption of botulinum toxin therapies and deep brain stimulation for refractory cases, along with innovations in drug formulations. While barriers such as diagnosis delays and treatment cost persist, strategic efforts by industry leaders like Ipsen and AbbVie are shaping market dynam",
    "url": "https://finance.yahoo.com/news/cervical-dystonia-research-analysis-report-153300521.html",
    "source": "GlobeNewswire",
    "provider": "yfinance",
    "raw": {
      "id": "7cdfda54-4044-379e-b932-3f0ed94825e9",
      "content": {
        "id": "7cdfda54-4044-379e-b932-3f0ed94825e9",
        "contentType": "STORY",
        "title": "Cervical Dystonia Research Analysis Report 2025-2035: Market Sees Intense Competition as Ipsen, Merz, and AbbVie Advance Therapies Through Strategic Expansions",
        "description": "",
        "summary": "The global cervical dystonia market is thriving, driven by increased disease prevalence, advancements in neuromodulation techniques, and heightened awareness of movement disorders. Key factors include the widespread adoption of botulinum toxin therapies and deep brain stimulation for refractory cases, along with innovations in drug formulations. While barriers such as diagnosis delays and treatment cost persist, strategic efforts by industry leaders like Ipsen and AbbVie are shaping market dynam",
        "pubDate": "2025-11-18T15:33:00Z",
        "displayTime": "2025-11-18T15:33:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc",
          "originalWidth": 480,
          "originalHeight": 58,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/_MlAqEncKPaKK77zrkRGmQ--~B/aD01ODt3PTQ4MDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 480,
              "height": 58,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/caWFqk489OEmv3xI33JamQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/globenewswire.com/93d5b27580f67db722dd7c112e43e8bc.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "GlobeNewswire",
          "url": "https://www.globenewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/cervical-dystonia-research-analysis-report-153300521.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/cervical-dystonia-research-analysis-report-153300521.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "IPN.PA"
            },
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T14:37:00+00:00",
    "headline": "Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3",
    "summary": "ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.",
    "url": "https://finance.yahoo.com/news/heres-neuroscience-drugs-aided-abbvies-143700828.html",
    "source": "Zacks",
    "provider": "yfinance",
    "raw": {
      "id": "c9e8ac52-48bc-3904-90f7-1459204d2244",
      "content": {
        "id": "c9e8ac52-48bc-3904-90f7-1459204d2244",
        "contentType": "STORY",
        "title": "Here's How Neuroscience Drugs Aided AbbVie's Top-line Growth in Q3",
        "description": "",
        "summary": "ABBV's neuroscience drugs drive strong Q3 momentum, with rising Botox Therapeutic sales, migraine therapies and new PD treatments fueling growth.",
        "pubDate": "2025-11-18T14:37:00Z",
        "displayTime": "2025-11-18T14:37:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227",
          "originalWidth": 635,
          "originalHeight": 400,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/OQG3.5Wd9P9R69q2rhm9rA--~B/aD00MDA7dz02MzU7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 635,
              "height": 400,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/pBlncPVBhEXpjxtBDlEOsg--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/zacks.com/dbd916198e87314e1ef238f8179e6227.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Zacks",
          "url": "http://www.zacks.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/heres-neuroscience-drugs-aided-abbvies-143700828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/heres-neuroscience-drugs-aided-abbvies-143700828.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "JNJ"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T17:47:00+00:00",
    "headline": "AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma",
    "summary": "AbbVie (NYSE: ABBV) today announced that EPKINLY® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide (EPKINLY + R2) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). This approval of EPKINLY is based on results from the pivotal Phase 3 EPCORE® FL-1 study that evaluated fixed duration EPKINLY + R2 compared to st",
    "url": "https://finance.yahoo.com/news/abbvie-announces-u-fda-approval-174700128.html",
    "source": "PR Newswire",
    "provider": "yfinance",
    "raw": {
      "id": "d818eae8-2298-327e-8640-a777218c707a",
      "content": {
        "id": "d818eae8-2298-327e-8640-a777218c707a",
        "contentType": "STORY",
        "title": "AbbVie Announces U.S. FDA Approval of EPKINLY® (epcoritamab-bysp) in Combination with Rituximab and Lenalidomide for Relapsed or Refractory Follicular Lymphoma",
        "description": "",
        "summary": "AbbVie (NYSE: ABBV) today announced that EPKINLY® (epcoritamab-bysp), a T-cell engaging bispecific antibody administered subcutaneously, in combination with rituximab and lenalidomide (EPKINLY + R2) is approved by the U.S. Food and Drug Administration (FDA) for the treatment of adult patients with relapsed or refractory (R/R) follicular lymphoma (FL). This approval of EPKINLY is based on results from the pivotal Phase 3 EPCORE® FL-1 study that evaluated fixed duration EPKINLY + R2 compared to st",
        "pubDate": "2025-11-18T17:47:00Z",
        "displayTime": "2025-11-18T17:47:00Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559",
          "originalWidth": 400,
          "originalHeight": 70,
          "caption": "AbbVie logo",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/g0d6LyVLzKGBfCQ5BSCPww--~B/aD03MDt3PTQwMDthcHBpZD15dGFjaHlvbg--/https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559.cf.webp",
              "width": 400,
              "height": 70,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/IUj902SDWZLhwmCbmJBNXA--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/prnewswire.com/a5eaa0af5f515703fe951de405417559.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "PR Newswire",
          "url": "https://www.prnewswire.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-announces-u-fda-approval-174700128.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-announces-u-fda-approval-174700128.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T20:44:55+00:00",
    "headline": "Sector Update: Health Care Stocks Rise Late Afternoon",
    "summary": "Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal",
    "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-204455650.html",
    "source": "MT Newswires",
    "provider": "yfinance",
    "raw": {
      "id": "9d64ed3a-d7d7-3083-b8bc-3bd04d2576cc",
      "content": {
        "id": "9d64ed3a-d7d7-3083-b8bc-3bd04d2576cc",
        "contentType": "STORY",
        "title": "Sector Update: Health Care Stocks Rise Late Afternoon",
        "description": "",
        "summary": "Health care stocks rose late Tuesday afternoon, with the NYSE Health Care Index up 0.3% and the Heal",
        "pubDate": "2025-11-18T20:44:55Z",
        "displayTime": "2025-11-18T20:44:55Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": null,
        "provider": {
          "displayName": "MT Newswires",
          "url": "https://www.mtnewswires.com/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-204455650.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/sector-health-care-stocks-rise-204455650.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            },
            {
              "symbol": "PFE"
            },
            {
              "symbol": "XLV"
            },
            {
              "symbol": "MDT"
            },
            {
              "symbol": "ARWR"
            },
            {
              "symbol": "DX-Y.NYB"
            },
            {
              "symbol": "MTSR"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": true,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  },
  {
    "ts": "2025-11-18T22:10:59+00:00",
    "headline": "Is AbbVie’s 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins?",
    "summary": "Wondering if AbbVie is a smart buy at today's price? You're not the only one. Let's dig into the numbers to find out how the market might be valuing the stock right now. AbbVie’s share price has jumped 7.0% in the past week and surged 30.4% year-to-date, putting its performance firmly in the spotlight and hinting at shifting investor sentiment. This momentum hasn’t come out of nowhere. Investors are reacting to positive developments from AbbVie’s drug pipeline and several high-profile FDA...",
    "url": "https://finance.yahoo.com/news/abbvie-30-2025-surge-justified-221059097.html",
    "source": "Simply Wall St.",
    "provider": "yfinance",
    "raw": {
      "id": "e4ea8481-d338-3531-875b-d5ed762d1753",
      "content": {
        "id": "e4ea8481-d338-3531-875b-d5ed762d1753",
        "contentType": "STORY",
        "title": "Is AbbVie’s 30% 2025 Surge Justified by Its Latest Drug Pipeline Wins?",
        "description": "",
        "summary": "Wondering if AbbVie is a smart buy at today's price? You're not the only one. Let's dig into the numbers to find out how the market might be valuing the stock right now. AbbVie’s share price has jumped 7.0% in the past week and surged 30.4% year-to-date, putting its performance firmly in the spotlight and hinting at shifting investor sentiment. This momentum hasn’t come out of nowhere. Investors are reacting to positive developments from AbbVie’s drug pipeline and several high-profile FDA...",
        "pubDate": "2025-11-18T22:10:59Z",
        "displayTime": "2025-11-18T22:10:59Z",
        "isHosted": true,
        "bypassModal": false,
        "previewUrl": null,
        "thumbnail": {
          "originalUrl": "https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd",
          "originalWidth": 1194,
          "originalHeight": 432,
          "caption": "",
          "resolutions": [
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/cbaG7tZ9A8mqrilci3AeIQ--~B/aD00MzI7dz0xMTk0O2FwcGlkPXl0YWNoeW9u/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 1194,
              "height": 432,
              "tag": "original"
            },
            {
              "url": "https://s.yimg.com/uu/api/res/1.2/1OA9tdPdimVe1Dv1fa4MAQ--~B/Zmk9c3RyaW07aD0xMjg7dz0xNzA7YXBwaWQ9eXRhY2h5b24-/https://media.zenfs.com/en/simply_wall_st__316/4451284b0632c6e74466a63400764edd.cf.webp",
              "width": 170,
              "height": 128,
              "tag": "170x128"
            }
          ]
        },
        "provider": {
          "displayName": "Simply Wall St.",
          "url": "https://simplywall.st/"
        },
        "canonicalUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-30-2025-surge-justified-221059097.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "clickThroughUrl": {
          "url": "https://finance.yahoo.com/news/abbvie-30-2025-surge-justified-221059097.html",
          "site": "finance",
          "region": "US",
          "lang": "en-US"
        },
        "metadata": {
          "editorsPick": false
        },
        "finance": {
          "stockTickers": [
            {
              "symbol": "ABBV"
            }
          ],
          "premiumFinance": {
            "isPremiumNews": false,
            "isPremiumFreeNews": false
          }
        },
        "storyline": null
      }
    }
  }
]